一个世纪的胆固醇和冠状动脉:从斑块到基因到他类药物
Joseph L Goldstein1, Michael S Brown1
1Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Cell
|March 28, 2015
概括
降低低密度脂蛋白 (LDL) 胆固醇对于预防冠心病死亡至关重要. 了解谁,何时和多长时间治疗LDL胆固醇是消除心脏病的关键.
科学领域:
- 心血管科学 心血管科学
- 代谢研究研究 代谢研究
- 遗传学 是一个遗传学.
背景情况:
- 冠心病 (CHD) 在工业化国家占死亡人数的很大一部分.
- 低密度脂蛋白 (LDL) 胆固醇已被确定为心脏病的主要致病原体.
- 肝脏的LDL受体 (LDLRs) 在调节血液中的LDL水平方面发挥着至关重要的作用.
研究的目的:
- 强调降低LDL胆固醇作为消除心血管疾病的主要目标的重要性.
- 突出有效的方法可用于减少LDL的可用性.
- 确定有关LDL治疗的关键临床问题:患者选择,时间和持续时间.
主要方法:
- 这项研究是对LDL胆固醇及其在心脏病中的作用现有研究的综述.
- 分析LDLR功能,LDL水平和心血管事件之间的关系.
- 确定影响高脂血症治疗决策的关键因素.
主要成果:
- 破坏LDLR功能的突变导致LDL升高和早期发作的心脏病发作.
- 增强的LDLR功能降低了LDL水平,降低了心脏病发作的发生率.
- 目前可以使用有效的干预措施降低LDL胆固醇.
结论:
- 降低LDL胆固醇是预防和消除心血管疾病的主要策略.
- 需要进一步的研究和临床指导方针来解决最佳的患者管理策略.
- 对谁进行治疗,何时进行治疗以及多长时间的问题的解决对于有效的心血管疾病预防至关重要.
相关概念视频
Cholesterol: Significance and Regulation
2.0K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
2.0K
Atherosclerosis I: Introduction
2.2K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.2K
Coronary Artery Disease I: Introduction
1.7K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.7K
Coronary Artery Disease II: Pathophysiology
1.0K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.0K
Coronary Artery Disease IV: Preventive Measures
879
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
879
Pharmacogenomics: Identification of New Drug Targets
94
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
94


